Jaime Hatcher Martin, MD
Neurology · Atlanta, GANPI 1649406380
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 99.2% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $65,355, more than ten times the $55 reported in 2019. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $753.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$164K
- Acadia Pharmaceuticals Inc$1K
- Boston Scientific$150
- Kyowa Kirin, Inc.$109
- Teva Pharmaceuticals USA, Inc.$43
- GE HealthCare$20
Across 1 payment — averaging $3510.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$4K
What the payments were for
- Consulting fees$69,34342%
- Speaking & faculty fees$73,05044%
- Travel & lodging$17,77111%
- Food & beverage$4,7483%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 214 | $163,540 |
| Acadia Pharmaceuticals Inc | 1 | $1,050 |
| Boston Scientific | 1 | $150 |
| Kyowa Kirin, Inc. | 1 | $109 |
| Teva Pharmaceuticals USA, Inc. | 1 | $43 |
| GE HealthCare | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,911 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 36 | $503,263 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 41 | $1,847 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 21 | $1,816 |
| Riluzole | 18 | $651 |
| Gabapentin | 15 | $392 |
| Bupropion XlBupropion Hcl | 11 | $372 |
| Risperidone | 11 | $189 |
Paid to pharmacies, not to this prescriber.
Other neurology in Atlanta
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Robert GilbertAtlanta$412K
- Lawrence SeidenAtlanta$272K
- Jacqueline RosenthalAtlanta$241K
- Ben ThrowerAtlanta$203K
- Andrei SerbanescuAtlanta$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.